Back to News
Market Impact: 0.3
Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Bolt Biotherapeutics announced a stock-for-stock acquisition of Prana Therapies to advance Prana’s pipeline of half-life-extended multispecific antibodies developed using its INSPIRE platform. The article provides no transaction value, financial terms, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
BOLT0.55
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features and More Sources for Document Search
- How to Evaluate AI Report Writers for Financial Analysis